ARAlexandra Razumovskaya

Alexandra Razumovskaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandra Razumovskaya has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Current State and Critical Challenges in Prostate Cancer Organoid Culture

    by Mariia Silkina, Maria Mastykina, Timur Kulagin, Margarita Beskhizhko, Alexandra Razumovskaya, Alina Shatsillo, Karina Klycheva, Nina Gorban, Oleg Karyakin, Vladimir Chaykov, et al.

    Three-dimensional prostate cancer organoids represent a promising platform for modeling tumor biology and personalizing therapeutic strategies. However, unlike many other solid tumors, reproducing this pathology in vitro is challenging. Despite initial culture establishment rates reaching 70-90% in certain studies, most cultures undergo early growth arrest (typically within passages P1-P3 or the first 1-2 months), accompanied by a high risk of losing the target tumor clone. In the present work, we provide a critical analysis of the current state of 3D prostate cancer culture technologies and attempt to identify the fundamental reasons for the inefficiency of standard multicomponent media and traditional extracellular matrices. Based on the analysis of single-cell transcriptomic profiling data, we characterized the adaptive drift of organoid cellular composition toward basal and transient states. Furthermore, we substantiated the critical need to modernize approaches for confirming model relevance, particularly by analyzing in detail the limitations of traditional markers. As an effective solution, we propose the concept of integrating multiplex expression test systems based on accessible quantitative PCR platforms, utilizing the extensive arsenal of highly informative RNA biomarkers accumulated in clinical urologic oncology. We conclude that the transition from empirical condition selection to directed niche reconstruction based on single-cell analysis data combined with PCR verification will open new opportunities for the widespread implementation of organoid models in basic research and clinical practice.

  • Open Access

    Optimization of a method for determination of docetaxel sensitivity using prostate cancer organoids

    by S. V. Nikulin, M. O. Silkina, A. V. Razumovskaya, M. P. Raygorodskaya, B. Ya. Alekseev

    Background. Analyzing the sensitivity of patient-derived tumor organoids to anti-cancer medications shows great potential for tailoring personalized treatment plans.Aim. To obtain two prostate tumor organoid cultures, optimize the composition of culture medium, and to evaluatethe efficacy of the chemotherapeutic drug docetaxel using the obtained organoid cultures.Materials and methods. The initial tissue was dissociated using the gentleMACS Octo homogenizer. The obtained cells were cultured in Matrigel with different culture media for selection of the optimal one. Cell viability and growth rates were assessed using the MTS assay.Results. In this study, we successfully obtained two organoid cultures of prostate cancer cells and identified the most effective composition of culture medium. Using a cytotoxic test, it was shown that the obtained organoid cultures of prostate cancer cells had different sensitivity to docetaxel which was reflected in different inhibition of the tumor cell growth rate.Conclusion. The utilization of prostate cancer organoids to determine the best treatment approach is a highly promising experimental technology. Nevertheless, additional research is required before integration of this technology into clinical practice.